Mar 24, 2011

Safety and Efficacy of Immunoglobulin: A Guide for Users, Assessors and Funders

This new IPOPI publication is now available for download on our website. Within a national healthcare system, selection of immunoglobulin (IG) therapies for conditions such as Primary Immunodeficiencies (PIDs) is difficult. In well-resourced countries, regulatory agencies make key decisions regarding such therapies' quality and safety; such regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA), are dedicated to assessing products and to granting marketing licenses. However, even in countries lacking resources to form such regulatory agencies, selection of IG therapies for IDs, within a national healthcare system, can occur. For such selection to occur, national regulatory authorities (NRAs) need to understand and to use several well-established principles; this guide offers such principles to NRAs and others who are responsible for selection of IG therapies for IDs, within their respective national healthcare systems. While this guide was written with IG therapies in mind, many of its principles apply to all plasma-derived medicinal products.

Download PDF

World PI Week
IPOPI would be grateful for any support to the important work for primary immunodeficiencies.

Read all

Executive Director: Johan Prevot
Tel/Fax: +351 21 407 5720
UK office
Firside Main Road Downderry
Cornwall PL11 3LE
United Kingdom

Tel: +44 1503 250 668
Fax: +44 1503 250 961
IPOPI is a charity registered in the UK.
Registration No. 1058005